UA63888C2 - Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence - Google Patents
Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence Download PDFInfo
- Publication number
- UA63888C2 UA63888C2 UA97126018A UA97126018A UA63888C2 UA 63888 C2 UA63888 C2 UA 63888C2 UA 97126018 A UA97126018 A UA 97126018A UA 97126018 A UA97126018 A UA 97126018A UA 63888 C2 UA63888 C2 UA 63888C2
- Authority
- UA
- Ukraine
- Prior art keywords
- nucleotide sequence
- plasmid
- sequence
- inhibitory
- cells
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 40
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 4
- 239000013598 vector Substances 0.000 title description 4
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 15
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims abstract description 14
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 63
- 238000001890 transfection Methods 0.000 claims description 29
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 206010048998 Acute phase reaction Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 143
- 210000004027 cell Anatomy 0.000 description 61
- 108700008625 Reporter Genes Proteins 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 38
- 108060001084 Luciferase Proteins 0.000 description 32
- 239000012634 fragment Substances 0.000 description 25
- 239000005089 Luciferase Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 230000006698 induction Effects 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000233803 Nypa Species 0.000 description 4
- 235000005305 Nypa fruticans Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108050005077 Haptoglobin Proteins 0.000 description 3
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000006713 insertion reaction Methods 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000006580 General Transcription Factors Human genes 0.000 description 2
- 108010008945 General Transcription Factors Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 235000006538 Opuntia tuna Nutrition 0.000 description 1
- 244000237189 Opuntia tuna Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000050796 human HP Human genes 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1995/001778 WO1996035782A1 (fr) | 1995-05-11 | 1995-05-11 | Inhibiteur de l'activite de il-6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA63888C2 true UA63888C2 (en) | 2004-02-16 |
Family
ID=8166014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA97126018A UA63888C2 (en) | 1995-05-11 | 1995-11-05 | Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6004813A (fr) |
| EP (1) | EP0824588B1 (fr) |
| JP (1) | JP4173539B2 (fr) |
| KR (1) | KR100449677B1 (fr) |
| AT (1) | ATE271128T1 (fr) |
| AU (1) | AU715125B2 (fr) |
| CA (1) | CA2220433C (fr) |
| DE (1) | DE69533264T2 (fr) |
| DK (1) | DK0824588T3 (fr) |
| ES (1) | ES2220929T3 (fr) |
| HK (1) | HK1016213A1 (fr) |
| IL (1) | IL118158A (fr) |
| MX (1) | MX9708663A (fr) |
| RU (1) | RU2205874C2 (fr) |
| UA (1) | UA63888C2 (fr) |
| WO (1) | WO1996035782A1 (fr) |
| ZA (1) | ZA963593B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0869176A4 (fr) * | 1995-11-07 | 2000-09-20 | Kaneka Corp | Autoantigenes |
| EP0855184A1 (fr) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination |
| US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| CA2323929C (fr) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Procedes et produits servant a stimuler le systeme immunitaire au moyen d'oligonucleotides et de cytokines immunotherapeutiques |
| EP0972780A1 (fr) * | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Peptides antagonistes de l'Il-6 |
| EP1113000A4 (fr) * | 1998-09-11 | 2004-12-15 | Ajinomoto Kk | Derives de benzene et leur utilisation medicale |
| AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US20030232813A1 (en) * | 2002-04-10 | 2003-12-18 | Orchid Chemicals & Pharmaceuticals Limited | Novel amino substituted pyrimidinone derivatives |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| CA2601884A1 (fr) * | 2005-03-18 | 2006-09-21 | Surendrakumar Satyanarayan Pandey | Nouveaux derives de tyrosine |
| US20080267888A1 (en) * | 2005-05-26 | 2008-10-30 | Pandey Surendrakumar Satyanara | Heterocyclic Derivatives |
| JP2008543968A (ja) * | 2005-06-28 | 2008-12-04 | オーキッド リサーチ ラボラトリーズ リミテッド | 新規なピラゾロピリミジノン誘導体 |
| BRPI0618399B1 (pt) | 2005-10-12 | 2023-10-03 | Morphosys Ag | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
| US7863446B2 (en) * | 2006-01-19 | 2011-01-04 | Orchid Research Laboratories Limited | Heterocycles |
| JP5237115B2 (ja) * | 2006-01-19 | 2013-07-17 | オーキッド リサーチ ラボラトリーズ リミテッド | 新規複素環類 |
| WO2008110891A2 (fr) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | Nouveaux dérivés hétérocycliques |
| US7943591B2 (en) * | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
| RU2572616C2 (ru) | 2008-02-01 | 2016-01-20 | Оркид Рисерч Лабораториз Лимитед | Новые гетероциклы |
| KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
| CN102596204B (zh) | 2009-07-06 | 2016-11-23 | 波涛生命科学有限公司 | 新的核酸前药及其使用方法 |
| WO2012039448A1 (fr) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | Groupe auxiliaire asymétrique |
| ES2626488T3 (es) | 2011-07-19 | 2017-07-25 | Wave Life Sciences Pte. Ltd. | Procedimientos para la síntesis de ácidos nucleicos funcionalizados |
| EP2846839B1 (fr) | 2012-05-10 | 2019-02-20 | Adynxx, Inc. | Formulations pour l'administration de principes actifs |
| EP2873674B1 (fr) | 2012-07-13 | 2020-05-06 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral |
| AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
| EP3095461A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| EP3095459A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
| CN106068325B (zh) | 2014-01-16 | 2021-07-09 | 波涛生命科学有限公司 | 手性设计 |
| PT3180434T (pt) | 2014-08-15 | 2019-10-29 | Adynxx Inc | Chamarizes oligonucleotídicos para o tratamento da dor |
-
1995
- 1995-05-11 DK DK95919438T patent/DK0824588T3/da active
- 1995-05-11 MX MX9708663A patent/MX9708663A/es unknown
- 1995-05-11 EP EP95919438A patent/EP0824588B1/fr not_active Expired - Lifetime
- 1995-05-11 RU RU97120584/13A patent/RU2205874C2/ru active
- 1995-05-11 DE DE69533264T patent/DE69533264T2/de not_active Expired - Lifetime
- 1995-05-11 US US08/945,726 patent/US6004813A/en not_active Expired - Lifetime
- 1995-05-11 AU AU25267/95A patent/AU715125B2/en not_active Expired
- 1995-05-11 AT AT95919438T patent/ATE271128T1/de active
- 1995-05-11 JP JP53368396A patent/JP4173539B2/ja not_active Expired - Lifetime
- 1995-05-11 KR KR1019970708022A patent/KR100449677B1/ko not_active IP Right Cessation
- 1995-05-11 CA CA2220433A patent/CA2220433C/fr not_active Expired - Lifetime
- 1995-05-11 WO PCT/EP1995/001778 patent/WO1996035782A1/fr active IP Right Grant
- 1995-05-11 ES ES95919438T patent/ES2220929T3/es not_active Expired - Lifetime
- 1995-11-05 UA UA97126018A patent/UA63888C2/uk unknown
-
1996
- 1996-05-06 IL IL11815896A patent/IL118158A/en not_active IP Right Cessation
- 1996-05-07 ZA ZA963593A patent/ZA963593B/xx unknown
-
1998
- 1998-11-09 HK HK98111831A patent/HK1016213A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990014681A (ko) | 1999-02-25 |
| EP0824588A1 (fr) | 1998-02-25 |
| CA2220433A1 (fr) | 1996-11-14 |
| JP4173539B2 (ja) | 2008-10-29 |
| IL118158A (en) | 2004-07-25 |
| RU2205874C2 (ru) | 2003-06-10 |
| EP0824588B1 (fr) | 2004-07-14 |
| ZA963593B (en) | 1996-11-25 |
| KR100449677B1 (ko) | 2004-11-20 |
| AU715125B2 (en) | 2000-01-20 |
| IL118158A0 (en) | 1996-09-12 |
| JPH11504816A (ja) | 1999-05-11 |
| AU2526795A (en) | 1996-11-29 |
| HK1016213A1 (en) | 1999-10-29 |
| DE69533264T2 (de) | 2004-11-25 |
| US6004813A (en) | 1999-12-21 |
| CA2220433C (fr) | 2010-02-16 |
| ATE271128T1 (de) | 2004-07-15 |
| DE69533264D1 (de) | 2004-08-19 |
| MX9708663A (es) | 1998-02-28 |
| ES2220929T3 (es) | 2004-12-16 |
| DK0824588T3 (da) | 2004-08-16 |
| WO1996035782A1 (fr) | 1996-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA63888C2 (en) | Nucleotide sequence, able to inhibit activity of il-6, use thereof for therapy, plasmide vector and pharmaceutical composition (alternatives) containing this nucleotide sequence | |
| Goldberg et al. | Activation of protein kinase C or cAMP‐dependent protein kinase increases phosphorylation of the c‐erbA‐encoded thyroid hormone receptor and of the v‐erbA‐encoded protein. | |
| Woloshin et al. | MSX1 inhibits MyoD expression in fibroblast× 10T½ cell hybrids | |
| MXPA97008663A (en) | Activity inhibitor i | |
| KR0148782B1 (ko) | 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터 | |
| Cameron et al. | Inhibition of gene expression by a short sense fragment | |
| Hillman et al. | Fragile XE-associated familial mental retardation protein 2 (FMR2) acts as a potent transcription activator | |
| JPH09510346A (ja) | 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子 | |
| Falzon et al. | Multiple protein-binding sites in an intracisternal A particle long terminal repeat | |
| KR102092981B1 (ko) | 조절된 유전자 발현 방법 | |
| Piatak et al. | Sequences locating the 5'ends of the major simian virus 40 late mRNA forms | |
| US7053194B2 (en) | Compositions and methods for p53-mediated repression of gene expression | |
| US5981188A (en) | Method for identifying agents that modulate transcription of human cytomegalovirus polymerase | |
| Shore et al. | Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential. | |
| US20060257367A1 (en) | Tumour-cell specific gene expression and its use in cancer therapy | |
| US5879879A (en) | CIS-acting element in the human LDL receptor promoter and uses thereof | |
| Stonestrom | Function of bromodomain and extra-terminal motif proteins (BETs) in GATA1-mediated transcription | |
| CA2227306A1 (fr) | Manipulation et detection de la proteine phosphatase 2c-pp2c.alpha.- expression dans des cellules cancereuses pour la prevention, la detection et la therapie du cancer | |
| AU2001279679A1 (en) | Tumour-cell specific gene expression and its use in cancer therapy | |
| US20050148502A1 (en) | Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 | |
| Canalis et al. | https://www. jbc. org/cgi/doi/10.1074/jbc. RA119. 011440 The latest version is at | |
| CALOTHY et al. | The 3í Untranslated Region of the Chicken c-src Protooncogene Modulates Gene Expression | |
| DiPietro et al. | 332. Routes of Ligand Administration That Give Efficient and Robust In Vivo Induction with the RheoSwitch® Therapeutic System | |
| Mawson | Transcriptional regulation of human topoisomerase II beta: a thesis presented to Massey University in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry | |
| GB2393183A (en) | Methods and means for promoting retroviral integration comprising inhibiting rad52 |